Treatment-related toxicities with fluosol-DA 20% infusion during radiation in advanced head and neck malignancies

Laryngoscope

Volumn 100, Issue 3, 1990, Pages 237-239

  Campbell, Bruce H ^a   Janjan, Nora A ^a   Byhardt, Roger W ^a   Toohill, Robert J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOSOL DA;

CANCER RADIOTHERAPY; CONFERENCE PAPER; HEAD AND NECK CANCER; HUMAN; METHODOLOGY; MUCOSA INFLAMMATION; OXYGENATION; PRIORITY JOURNAL; RADIATION NECROSIS;

BLOOD SUBSTITUTES; CARCINOMA, SQUAMOUS CELL; DRUG COMBINATIONS; FLUOROCARBONS; HEAD AND NECK NEOPLASMS; HUMAN; INFUSIONS, INTRAVENOUS; MULTICENTER STUDIES; OXYGEN INHALATION THERAPY; RADIATION INJURIES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; RANDOM ALLOCATION; STOMATITIS;

EID: 0025208334     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1288/00005537-199003000-00005     Document Type: Article

References (4)

1. Henk, J.M.: Does Hyperbaric Oxygen Have a Future in Radiation Therapy? Int J Radiat Oncol Biol Phys, 7:1125-1128, 1981.
2. Naito, R. and Yokoyama, K.: Perfluorochemical Blood Substitutes, Fluosol-43, Fluosol-DA, 20% and 35%. The Green Cross Corporation Technical Information Series, Number 5, June, 1978.
3. Matsumoto, T., Wantabe, M., Yokoyama, K., et al.: Further Studies on Toxicity of Fluosol-DA. Proceedings of the Symposium on Research on PFC in Medicine and Biology. Stockholm, 1977.
4. Anderson, H., Leimgruber, P., Roubin, G., et al.: Distal Coronary Perfusion During Percutaneous Transluminal Coronary Angioplasty. Am Heart J, 110:720-726,1985.